With the new sister company Ayass Pharmaceutical, LLC, we are  strengthening the foundation of Dr. Ayass’ mission to Bridge Science and Precision Patient Care. We are well positioned to advance our development efforts for a NEW drug Synaptazine to treat Alzheimers.

Synaptazine: prevents cell damage, causes cells to form new connections (reversing damage), provides cellular energy, increases lifespan and locomotor ability.